Other Intangible Assets, Net (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011	Dec. 31, 2010
Intangible Assets (Excluding Goodwill) [Line Items]
Amortized intangible assets	$ 3,303.2		$ 3,303.2		$ 3,233.9
Total amortized and unamortized intangible assets, gross	3,581.1		3,581.1		3,353.7
Less: Accumulated amortization	(955.5)		(955.5)		(860.7)
Other intangible assets, net	2,625.6	2,679.4	2,625.6	2,679.4	2,493.0	1,978.9
Other Disclosures
Impairment of intangible assets	27.0	0	27.0	0
Estimated future intangible assets amortization charge - Year 1	202.6		202.6
Estimated future intangible assets amortization charge - Year 2	202.6		202.6
Estimated future intangible assets amortization charge - Year 3	202.6		202.6
Estimated future intangible assets amortization charge - Year 4	202.6		202.6
Estimated future intangible assets amortization charge - Year 5	202.6		202.6
Currently Marketed Products
Intangible Assets (Excluding Goodwill) [Line Items]
Amortized intangible assets	2,548.1		2,548.1		2,500.7
Acquired Product Technology
Intangible Assets (Excluding Goodwill) [Line Items]
Amortized intangible assets	710.0		710.0		710.0
Other Intangible Assets
Intangible Assets (Excluding Goodwill) [Line Items]
Amortized intangible assets	45.1		45.1		23.2
IPR&D
Intangible Assets (Excluding Goodwill) [Line Items]
Uamortized intangible assets	277.9		277.9		119.8
Regenerative Medicine
Intangible Assets (Excluding Goodwill) [Line Items]
Other intangible assets, net	696.4		696.4		691.5
Specialty Pharmaceuticals
Intangible Assets (Excluding Goodwill) [Line Items]
Other intangible assets, net	1,444.7		1,444.7		1,348.3
Human Genetic Therapies
Intangible Assets (Excluding Goodwill) [Line Items]
Other intangible assets, net	$ 484.5		$ 484.5		$ 453.2